Hydralazine

Overview

Hydralazine is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine inhibits NOS-2 ( iNOS ) and COX-2 , and reduces the production of NO and PGE E2 ; meanwhile, Hydralazine scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine has been widely used in studies on hypertension, various cancers (such as cervical cancer , leukemia), spinal cord injury and the mechanisms of inflammatory pain.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Nervous System Injury | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pain | Products > Disease Areas > CNS Infection | Products > Disease Areas > Spinal Cord Injury | Products > Disease Areas > Hypertension | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PGE synthase | Products > Signaling Pathways > DNA Methyltransferase | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > COX | Products > Signaling Pathways > NO Synthase

Product Information

• Catalog No.: HY-B0464A
• CAS No.: 86-54-4
• Molecular Formula: C8H8N4
• Molecular Weight: 160.18
• Purity: 99.94%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2 mg/mL (12.49 mM); Clear solution
• Availability: In-stock

Source

Original product source